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Zaburzenia metabolizmu glukozy u pacjentów z hormonalnie nieczynnymi 
gruczolakami nadnerczy — doświadczenie jednego ośrodka
Katarzyna Krzyżewska, Ewa Niemczuk, Bartosz Jakub Myśliwiec, Roman Junik
Department of Endocrinology and Diabetology, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz
Abstract
Introduction: The presence of glucose metabolism disorders and their possible correlation with degree of cortisol secretion were evaluated 
in patients with non-functioning adrenal incidentalomas (NFAIs).
Material and methods: The study group consisted of 131 patients with hormonally inactive adrenal incidentalomas. In each patient, 
besides hormonal and radiological evaluation, was assessed for fasting glucose and insulin concentrations, and the oral glucose toler-
ance test (OGTT) was performed in all participants without previous history of glucose disturbances. The HOMA-IR, QUICKI, and TyG 
indices were calculated. 
Results: Diabetes was diagnosed in 30.5% of the studied group. Among glucose tolerance abnormalities, impaired fasting glucose (IFG) 
was found in 23.7%, impaired glucose tolerance (IGT) in 4.6%, and combined IFG and IGT in 11.5%. Normoglycaemia was recognised in 
29.8% of NFAIs patients. The occurrence rate of glucose aberrations increased with age. There was a significant difference in all insulin 
resistance indices shown between normoglycaemic patients and those with impairments in glucose tolerance. There was no significant 
correlation between fasting glucose, insulin resistance indices, and adrenal tumour size or degree of cortisol secretion.
Conclusions: The prevalence of diabetes and impaired fasting glucose among NFAIs patients is much higher than in the general population. 
Therefore, patients with incidentally discovered adrenal tumours should be tested for glucose tolerance. (Endokrynol Pol 2017; 68 (4): 416–421)
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Streszczenie
Wstęp: Chorych z nieczynnymi hormonalnie incydentaloma nadnerczy (NFAI, non-functioning adrenal incidentaloma) zbadano pod kątem 
obecności zaburzeń metabolizmu i ich potencjalnych korelacji z poziomem sekrecji kortyzolu.
Materiał i metody: Badana grupa składała się ze 131 chorych z nieczynnymi hormonalnie incydentaloma nadnerczy. U każdego pacjenta 
oprócz oceny czynności hormonalnej i badań radiologicznych zmierzono glikemię na czczo oraz stężenie insuliny na czczo, a u osób 
bez zaburzeń gospodarki węglowodanowej w wywiadzie wykonano doustny test tolerancji glukozy (OGTT, oral glucose tolerance test). 
Obliczono wskaźniki HOMA-IR, QUICKI i TyG. 
Wyniki: U 30,5% badanych rozpoznano cukrzycę. U części chorych stwierdzono inne zaburzenia gospodarki węglowodanowej — u 23,7% 
nieprawidłową glikemię na czczo (IFG, impaired fasting glucose), u 4,6% nieprawidłową tolerancję glukozy (IGT, impaired glucose tolerance), 
a u 11,5% skojarzenie IFG i IGT. Normoglikemię stwierdzono u 29,8% pacjentów z NFAI. Częstość zaburzeń metabolizmu glukozy wzrasta 
z wiekiem. Wykazano istotną różnicę wartości wszystkich wskaźników insulinooporności między osobami z normoglikemią a pacjentami 
z nieprawidłowościami w zakresie tolerancji glukozy. Nie zaobserwowano istotnych korelacji między glikemią na czczo ani wskaźnikami 
insulinooporności a wielkością guza nadnerczy lub poziomem sekrecji kortyzolu.
Wnioski: Częstość występowania cukrzycy i nieprawidłowej glikemii na czczo u chorych z NFAI była znacznie wyższa niż w populacji 
ogólnej. Dlatego u chorych z przypadkowo wykrytymi guzami nadnerczy należy wykonać test tolerancji glukozy. (Endokrynol Pol 2017; 
68 (4): 416–421)
Słowa kluczowe: nieczynny hormonalnie gruczolak nadnerczy, cukrzyca, nieprawidłowa glikemia na czczo, nieprawidłowa tolerancja glukozy
Introduction
In recent years, imaging technique improvement has 
led to an increase in the number of adrenal inciden-
talomas (AIs). Although different authors have used 
various definitions, the majority of them agree that AI is 
a mass discovered by diagnostic testing or treatment for 
unrelated disorders. By definition, patients with AIs do 
not show signs and symptoms of hormonal hypersecre-
tion. However, even subtle forms of hormonal excess, 
especially cortisol secretion, may be associated with or 
be a marker of premature morbidity and mortality [1]. 
Moreover, patients with adrenal masses considered 
as hormonally inactive by endocrine evaluation often 
suffer from hypertension, dyslipidaemia, glucose in-
tolerance, and obesity, all parameters closely linked to 
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insulin resistance [2]. There is a continuing dilemma 
of whether a metabolic disturbance is seen more often 
in non-functioning adrenal incidentalomas (NFAIs) 
or whether it is a result of undetectable glucocorti-
coid hypersecretion. It has been proposed that NFAIs 
might be an unrecognised manifestation of metabolic 
syndrome [3, 4].
The aim of the study was to appraise the abnor-
malities in carbohydrate metabolism in consecutive 
patients with non-functioning adrenal adenomas 
and their possible correlation with degree of cortisol 
secretion.
Material and methods
The study group consisted of 131 consecutive patients 
with adrenal incidentalomas diagnosed between No-
vember 2014 and February 2016 at the Department of 
Endocrinology and Diabetology of University Hospital 
No. 1 in Bydgoszcz. Inclusion criteria considered: 
 — normal overnight low-dose dexamethasone sup-
pression test (1 mg, orally, at 11 p.m. and measure-
ment of serum cortisol at 8 a.m. the following morn-
ing) when morning cortisol fell below 1.8 µg/dL;
 — when post-dexamethasone serum cortisol concen-
tration was over 1.8 µg/dL the absence of cortisol 
excess in other tests was required:
• normal 24-hour urinary free cortisol, morning 
adrenocorticotropin (ACTH), and midnight cor-
tisol measurements,
• normal plasma renin activity and aldosterone 
levels during postural change,
• normal 24-hour urinary excretion of catechola-
mines,
• CT characteristics suggested adenoma (lesions 
with a radiation attenuation coefficient ≤ 10 HU).
An oral glucose tolerance test (OGTT) was per-
formed in all participants without previous history 
of glucose disturbances. The fasting insulin level and 
glycated haemoglobin (HbA1c) were assessed as well. 
Insulin resistance and insulin sensitivity were evalu-
ated using the HOMA-IR and QUICKI indices with 
the following validated formulas: homeostasis model 
assessment — HOMA-IR = fasting insulin (µIU/ml) 
x fasting glucose (mmol/L)/22.5 and the quantitative 
insulin sensitivity check index — QUICKI= 1/[log fast-
ing insulin (µIU/mL) + log fasting glucose (mg/dL)] 
[5]. An alternative insulin resistance (IR) estimator was 
used also, such as the triglyceride glucose (TyG) index, 
calculation of which was based on fasting plasma 
glucose and triglyceride. TyG index correlated with 
adiposity, and metabolic and atherosclerosis markers 
related to IR, and it presented good correlations with 
euglycaemic clamp. The TyG index was calculated as 
Ln [fasting triglycerides(mg/dL) x fasting glucose (mg/ 
/dL)/2] [6, 7].
Patients with fasting glucose concentration ≥ 100 
mg/dL but < 126 mg/dL were considered as having 
impaired fasting glucose (IFG). Patients with two-hour 
post-load glucose level ≥ 140 mg/dL but < 200 mg/dL 
were considered as having impaired glucose tolerance 
(IGT). Diagnosis of diabetes was established if the 
subject had a prior diagnosis or had been treated with 
hypoglycaemic agents. The patients received 75 g OGTT 
and were diagnosed with diabetes mellitus if the glucose 
value was ≥ 200 mg/dL after two hours. Currently, Dia-
betes Poland (PTD) does not recommend measuring the 
haemoglobin A1c level to diagnose diabetes in the Polish 
population due to inadequate quality control of labora-
tory methods and unclear cut-off values of HbA1c [8]. 
However, following American Diabetes Association 
guidelines, a haemoglobin A1c range of 5.7% to 6.4% 
may indicate individuals with an increased chance 
of developing diabetes [9]. There was also observed 
a progressively increased risk of diabetes in subjects 
with TyG index levels of 8.31 and more [10]. In another 
study participants were classified into the metabolically 
obese but normal weight (MONW) and characterised 
with higher susceptibility to type 2 diabetes and car-
diovascular diseases with TyG index above 8.82 for men 
and 8.73 for women [11]. The normal HOMA-IR range 
was < 2.5. The reported values of QUICKI were 0.382 ± 
0.007 for non-obese, 0.331 ± 0.010 for obese, and 0.304 
± 0.007 for diabetic individuals [5].
Statistical analysis
The measured parameters were checked for normality 
of distribution by the Shapiro-Wilk test. Values are pre-
sented as mean ± standard deviation (SD) or median 
(25th and 75th percentiles) if not normally distributed. 
A comparison of the variables was performed using the 
ANOVA with Tukey post hoc test and the Kruskal-Wallis 
ANOVA test. The relationship between parameters was 
tested with Spearman’s correlation. P values < 0.05 
were defined as statistically significant.
Results
Of the 131 patients (79 females and 52 males) with 
adrenal incidentalomas (99 unilateral and 32 bilateral, 
with mean diameter 21 mm), 92 (70.2%) had glucose 
disturbances (Fig. 1). Forty participants (30.5%) were 
classified as having diabetes mellitus (eight newly dia-
gnosed cases). Among the glucose intolerance group 
impaired fasting glucose (IFG) was diagnosed in 31 
cases, impaired glucose tolerance (IGT) in six cases, and 
combined IFG and IGT in 15 cases. Normoglycaemia 
was recognised in 39 patients (29.8%).
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When normoglycaemic patients and with impair-
ments in glucose tolerance were compared, no sig-
nificant differences in sex, tumour size (p = 0.1587), 
midnight serum cortisol (p = 0.2974), 24-hour urinary 
free cortisol (p = 0,2842), plasma ACTH (p = 0.2566), 
and post-dexamethasone serum cortisol (p = 0.8040) or 
fasting insulin concentration (p = 0.1213) were detected.
The groups showed statistically significant differ-
ences in age (normoglycaemic vs. glucose intolerance 
group p = 0.0347; normoglycaemic vs. diabetes mellitus 
group p < 0.0001) (Fig. 2), waist circumference (p = 
0.0189; p = 0.0037 in the above compared subgroups), 
and BMI (normoglycaemic vs. diabetes mellitus group 
p = 0.0015). The average age of patients with diabetes 
mellitus was 67.4 ± 8.2 years, whereas the average age 
of those with normoglycaemia was 58.8 ± 8.3 years. 
The highest prevalence of diabetes (≥ 50%) was found 
among females aged ≥ 70 years (Fig. 3) and males aged 
≥ 60 years (Fig. 4). In contrast, there was no case of 
diagnosed diabetes among patients under 50 years of 
age. About 87% of patients with diabetes mellitus and 
86% of those with glucose intolerance were overweight 
or obese with abdominal fat distribution. 
The median (25th and 75th percentiles) of HOMA-IR 
in patients with normoglycaemia, glucose intolerance, 
and overt diabetes was 1.74 (1.28; 2.77), 2.84 (1.87; 3.71), 
and 2.58 (1.50; 4.20), respectively. The median QUICKI 
(25th and 75th percentiles) in the abovementioned sub-
groups was 0.305 (0.304; 0.307), 0.299 (0.298; 0.301), 
and 0.296 (0.290; 0.300), respectively. The mean value 
of TyG index in compared subjects was 8.57 ± 0.50, 
8.90 ± 0.39, and 9.01 ± 0.40. There was a significant 
difference in all insulin resistance indices shown be-
tween normoglycaemic and glucose intolerance groups 
Figure 1. Prevalence of glucose disturbances in the studied group
Rycina 1. Występowanie zaburzeń gospodarki węglowodanowej 
w badanej grupie
Figure 4. Prevalence of glucose disturbances in males by age
Rycina 4. Występowanie zaburzeń gospodarki węglowodanowej 
u mężczyzn w zależności od wieku
Figure 3. Prevalence of glucose disturbances in females by age
Rycina 3. Występowanie zaburzeń gospodarki węglowodanowej 
u kobiet w zależności od wieku
Figure 2. Age of non-functioning adrenal incidentaloma (NFAIs) 
patients with normoglycaemia (NG), impaired fasting glucose (IFG), 
impaired glucose tolerance (IGT), IFG & IGT, and diabetes mellitus (DM)
Rycina 2. Wiek pacjentów z nieczynnymi hormonalnie guzami 
nadnerczy z prawidłową glikemią (NG), nieprawidłową glikemią 
na czczo (IFG), nieprawidłową tolerancją glukozy (IGT), IFG & 
IGT oraz cukrzycą (DM)
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(p = 0.0032 for HOMA-IR, p < 0.0001 for QUICKI, 
p = 0.0021 for TyG index), and between normoglycaemic 
and overt diabetic individuals (p = 0.0332 for HOMA-IR, 
p < 0.0001 for QUICKI and TyG index). Subgroups with 
impairments in glucose tolerance presented no statis-
tical difference in IR markers (p = 1.0 for HOMA-IR, 
p = 0.2168 for QUICKI, p = 0.4513 for TyG index).
Anthropometric and selected biochemical and 
hormonal characteristics of the target population are 
shown in Table I. 
Generally, there was no significant correlation 
either between fasting glucose, insulin resistance in-
dices and tumour size, midnight serum cortisol, and 
post-dexamethasone cortisol. Interestingly in normo-
glycaemic individuals midnight serum cortisol nega-
tively correlated with adrenal tumour size (R = –0.32, 
p = 0.0438) and TyG index (R = –0.42, p = 0.0070). There 
was no such correlation in the remaining subgroups or 
between cortisol and HOMA-IR or QUICKI. Moreover, 
in diabetic subjects, post-dexamethasone serum corti-
sol positively correlated with tumour size (R = 0.43, 
p = 0.0084) and negatively correlated with HOMA-IR 
(R = –0.43, p = 0.0159). Some positive correlation 
between tumour size and post-dexamethasone serum 
cortisol was shown also in the glucose intolerant group 
(R = 0.27, p = 0.0689) but not in the normoglycaemic 
group (R = 0.10, p = 0.5542).
 Discussion
Our study shows that insulin resistance and related 
complications such as altered glucose metabolism are 
common in patients with hormonally inactive adrenal 
incidentalomas. The participants were not adjusted for 
body weight or age, and no control group was included, 
which is the main limitation of the study because we 
examined consecutive, unselected patients with adrenal 
incidentalomas.
Table I. Selected clinical, biochemical, and hormonal features in patients with non-functioning adrenal incidentalomas
Tabela I. Wybrane cechy kliniczne, biochemiczne i hormonalne u pacjentów z hormonalnie nieczynnymi incydentaloma nadnerczy
 1 
Normal glucose 
tolerance 
(n = 39)
2 
Glucose intolerance 
(IFG +IGT) 
(n = 52)
3 
Diabetes 
mellitus 
(n = 40)
p value
1 vs. 2 1 vs. 3 2 vs. 3
Age [years] 58.8 ± 8.3 63.3 ± 7.6 67.4 ± 8.2 p = 0.0347 p < 0.0001 p = 0.0585
Sex [M/F] 14/25 23/29 15/25
BMI [kg/m2] 27.6 ± 4.0 30 ± 4.6 31.7 ± 6.7 p = 0.1059 p = 0.0015 p = 0.3123
Waist circumference [cm] 93.8 ± 11.5 101.5 ± 11.6 103 ± 15.1 p = 0.0189 p = 0.0037 p = 0.8592
SBP [mmHg] 131.3 ± 17.9 133,9 ± 22.6 145 ± 18.2 p = 0.8264 p = 0.0068 p = 0.0354
DBP[mmHg] 81.7 ± 11.6 80.7 ± 11.2 82.7 ± 12.2 p = 0.7441
Fasting glucose [mg/dL]* 90.0 (78.0; 99.0) 105.0 (101.0; 108.0) 113.5 (103.0; 
135.5)
p < 0.0001 p < 0.0001 p < 0.0001
Fasting insulin [µIU/mL]* 8.4 (5.9; 12.6) 10.6 (7.5; 14.0) 9.5 (5.9; 15.5) p = 0.1213
HbA1c [%]* 5.5 (5.3; 5.6) 5.7 (5.5; 5.9) 6.3 (5.8; 6.8) p = 0.0304 p < 0.0001 p = 0.0001
HOMA-IR* 1.74 (1.28; 2.77) 2.84 (1.87; 3.71) 2.58 (1.50; 4.20) p = 0.0032 p = 0.0332 p = 1.0
QUICKI* 0.305 (0.304; 0.307) 0.299 (0.298;0.301) 0.296  
(0.290; 0.300)
p < 0.0001 p < 0.0001 p = 0.2168
TyG index 8.57 ± 0.50 8.90 ± 0.39 9.01 ± 0.40 p = 0.0021 p < 0.0001 p = 0.4513
UFC [µg/day]* 38.0 (30.0; 69.0) 49.1 (26.3; 72.8) 40.2 (23.4; 50.4) p = 0.2842
Midnight serum cortisol 
[µg/dL]*
3.0 (2.2; 4.6) 3.7 (2.4; 6.4) 4.0 (3.1; 5.4) p = 0.2974
Post-dexamethasone 
serum cortisol [µg/dL]*
1.42 ± 0.62 1.42 ± 0.60 1.49 ± 0.60 p = 0.8040
ACTH [pg/mL]* 15.5 (9.8; 30.1) 15.5 (9.3; 26.0) 22.1 (12.2; 30.9) p = 0.2566
Tumour size [mm]* 19.0 (12.0; 23.0) 20.0 (15.5; 29.0) 17.0 (12.0; 25.5) p = 0.1587
Unilateral/bilateral tumours 31/8 39/13 29/11
Values are expressed as mean ± SD, unless otherwise indicated. * Values are median (25th and 75th percentile). IFG — impaired fasting glucose; IGT — impaired 
glucose tolerance; BMI — body mass index; SBP — systolic blood pressure; DBP — diastolic blood pressure; HbA1c — glycated haemoglobin A1c; HOMA-IR  
— homeostasis model assessment; QUICKI — quantitative insulin sensitivity check index; TyG — the product of fasting triglyceride and glucose; UFC — 24-hour 
urinary free cortisol; ACTH — adrenocorticotropin
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In our study the incidence of diabetes mellitus in 
NFAIs occurred 4.5 times more often (30.5% vs. 6.7%) 
and impaired fasting glucose was 2.2-fold higher (35% 
vs. 15.6%) than in the general Polish population [12]. 
Similarly, according to the Diabetes Atlas, the preva-
lence of diabetes in Poland was about 6–7%. When 
dividing the European population by age (20–29, 30–39, 
40–49, 50–59, 60–69, 70–79 years) and sex, the highest 
percentage of diabetes (20–25%) was among males 
aged 60 years and over and females aged 70 years and 
over [13]. In our incidentaloma patients there was about 
a 1.5–2.0-fold higher occurrence rate of glucose aberra-
tions in three subgroups divided by aged (50–59, 60–69, 
≥ 70 years). Moreover, obesity and arterial hypertension 
were strong predictors of alterations in glucose metabo-
lism, such as in the NATPOL 2011 Study. In prior studies 
higher prevalence of metabolic syndrome parameters 
was reported in NFAI patients [14].
Previously, it was shown that patients with NFAIs 
have a high prevalence of disturbed glucose tolerance, 
lower than that described for Cushing’s syndrome, 
but higher than expected. Fernandez-Real et al. [15] 
revealed that cortisol concentration, both basal and 
post-dexamethasone, was similar in patients with 
normal and altered glucose tolerance. Our study also 
did not expose a significant difference in cortisol secre-
tory in all subgroups. However, these results are not 
sufficient argument against the possibility of the influ-
ence of cortisol production on glucose metabolism. We 
cannot rule out that methods used for measurement 
of glucocorticoids are not sensitive enough to detect 
their subtle excess. 
A study by Ivović et al. [16] showed that there was 
no difference between subjects with subclinical Cushing 
syndrome (SCS) and NFAIs for all tested indices of insu-
lin resistance (IR): HOMA, QUICKI, TyG, ISI-composite, 
and G/I, and that post-dexamethasone serum cortisol 
cannot be used as a predictor of HOMA. In support of 
their findings, Morelli et al. unveiled no differentiation 
in the presence of arterial hypertension, diabetes mel-
litus, dyslipidaemia, abdominal obesity, or metabolic 
syndrome between the two above groups. Moreover, 
Morelli et al. suggested that glucocorticoid receptor 
polymorphism in patients with adrenal incidentaloma 
may play a role in determining the metabolic complica-
tions related to overt cortisol excess [17]. 
Midorikawa et al. [18] demonstrated an improve-
ment in blood pressure, glucose tolerance, and insulin 
resistance after adrenalectomy in patients with SCS 
and NFAIs, suggesting that metabolic disorder may 
be associated with adrenocortical adenoma and might 
be part of its pathophysiology even if the tumour has 
been diagnosed as non-functioning by endocrinologi-
cal examination. Muscogiuri et al. revealed correlation 
between insulin resistance and free urinary cortisol, 
ACTH, and serum cortisol after 1-mg dexamethasone 
suppression, demonstrating that although there are no 
overt clinical abnormalities, there may be subtle distur-
bances of cortisol steroid secretion. They also found 
correlation between degree of insulin resistance and 
adrenal tumour size, prompting the mass size as the 
most powerful predictor of insulin resistance. Moreover, 
there was the hypothesis that clinically undetectable 
hypercortisolism might be responsible for insulin resist-
ance and hyperinsulinaemia might induce growth of 
tumour [2]. In our study we did not find differences in 
metabolic symptoms in patients with NFAIs in relation 
to the size of the tumour, which is in agreement with 
the study by Lazurova et al. [19].
Conclusions
The main outcome of this study was a remarkably 
higher prevalence of disturbed glucose tolerance among 
subsequent unselected patients with non-functioning 
adrenal adenomas than that found in the general Polish 
population. According to the present data, the unex-
pected finding of adrenal tumour should encourage 
clinicians to diagnose early and treat possible abnor-
malities in glucose homeostasis. 
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